Pig ALB ELISA Kit

Cloud computing is characterized by efficient provision of services and access to shared resources through its pay-per-use model. The service brokers in this architecture mediate among cloud users and cloud service providers to redirect requests to appropriate data centers while aiming at minimization of response time and monetary cost for cloud users. For selection of data centers, the optimization techniques incur large overhead during execution of applications. Consequently, the recent brokering approaches resort to heuristics which do not guarantee optimal solutions in terms of response time and cost that are pivotal for executing compute intensive applications in a cloud environment. In this paper, we propose multi-objective service brokering with availability-based load balancing (MOSB_ALB) approach that minimizes response time and monetary cost for efficient low-cost provision of services in a cloud environment. The MOSB_ALB approach performs static and dynamic selection of data centers while using availability-based load balancing for distributing load among virtual machines. The static computation of data center index incorporates MOEA/D algorithm and usesz-score values corresponding to indexes in optimal solutions. The dynamic computation of data center indexes uses criteria based on weights and allocation counts. The experimentation performed through a large number of configurations shows that the MOSB_ALB approach outperforms existing well-known cloud service brokering approaches by improving cumulative response time with a speedup factor of 2.19, along with a significant reduction of monetary cost.

The purpose of this study was to investigate the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) treatment in Chinese hepatocellular carcinoma (HCC) patients and the prognostic factors for treatment response as well as survival. A total of 275 HCC patients were included in this prospective study. Treatment response was assessed by modified Response Evaluation Criteria in Solid Tumors (mRECIST), and progression-free survival (PFS) as well as overall survival (OS) were determined. Liver function and adverse events (AEs) were assessed before and after DEB-TACE operation. Complete response (CR), partial response (PR), and objective response rate (ORR) were 22.9%, 60.7%, and 83.6%, respectively. The mean PFS was 362 (95% CI: 34.9-375) days, the 6-month PFS rate was 89.4 +/- 2.1%, while the mean OS was 380 (95% CI: 370-389) days, and the 6-month OS rate was 94.4 +/- 1.7%. Multivariate logistic regression revealed that portal vein invasion (p= 0.011) was an independent predictor of worse clinical response. Portal vein invasion (p= 0.040), previous cTACE treatment (p=0.030), as well as abnormal serum creatinine level (BCr) (p= 0.017) were independent factors that predicted worse ORR. In terms of survival, higher Barcelona Clinic Liver Cancer (BCLC) stage (p= 0.029) predicted for worse PFS, and abnormal albumin (ALB) (p=0.011) and total serum bilirubin (TBIL) (p= 0.009) predicted for worse OS. The number of patients with abnormal albumin, total protein (TP), TBIL, alaninc aminotransferase (ALT), and aspartate aminotransferase (AST) were augmented at 1 week posttreatment and were similar at 1-3 months compared with baseline. The most common AEs were pain, fever, nausea, and vomiting, and no severe AEs were observed in this study. DEB-TACE was effective and tolerable in treating Chinese HCC patients, and portal vein invasion, previous cTACE treatment, abnormal BCr, ALB, and TBIL appear to be important factors that predict worse clinical outcome.